Dr. Aric C. Hall, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Wisconsin School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 157
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Wisconsin School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 57256
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Wi Hospitals & Clinics Authority Madison, WI
Medical groups
- University of Wisconsin Medical Foundation Inc (2,553 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 157
- Services billed
- 723
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 237 | 88 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 138 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 50 |
| Insertion of needle into vein for collection of blood sample | 31 | 13 |
| Established patient office or other outpatient visit, 40-54 minutes | 27 | 22 |
| Hospital discharge day management, 30 minutes or less | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Madison, WI | 472 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Madison, WI | 89 |
| Jakafi (ruxolitinib phosphate) | 77 |
| Famotidine Other prescribers in Madison, WI | 58 |
| Duloxetine Hcl Other prescribers in Madison, WI | 54 |
| Lenalidomide | 53 |
| Dexamethasone Other prescribers in Madison, WI | 45 |
| Gabapentin Other prescribers in Madison, WI | 43 |
| Omeprazole Other prescribers in Madison, WI | 41 |
| Eliquis (apixaban) Other prescribers in Madison, WI | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $1,596 in total to this clinician.
| National Marrow Donor Program | $1,596 |
|---|
| Travel and Lodging | $1,373 |
|---|---|
| Food and Beverage | $222 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| National Marrow Donor Program Dec 5, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $666 |
| National Marrow Donor Program Nov 7, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $490 |
| National Marrow Donor Program Oct 13, 2025 | Travel and Lodging travel to Herndon, VA · in-kind | $217 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $151,280 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
Syndax Pharmaceuticals, Inc. - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.